FDA Oncology Announcements

Multi-ingredient × Genitourinary × Clear all

2 Announcements

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer

Trial: AMPLITUDE
Drug: Akeega (niraparib and abiraterone acetate) · Multi-ingredient
Condition: Genitourinary

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

Trial: MAGNITUDE
Drug: Akeega (niraparib and abiraterone acetate) · Multi-ingredient
Condition: Genitourinary